ORIC Pharmaceuticals, Inc. (ORIC)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in ORIC Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

ORIC Pharmaceuticals, Inc. (ORIC) has returned 54.89% so far this year and 127.06% over the past 12 months.

Based on dividend-adjusted daily data since Apr 24, 2020, ORIC's average daily return is +0.10%, while the average monthly return is +1.75%. At this rate, your investment would double in approximately 3.3 years.

Historically, 47% of months were positive and 53% were negative. The best month was Dec 2022 with a return of +64.1%, while the worst month was Jul 2020 at -40.5%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 5 months.

On a daily basis, ORIC closed higher 46% of trading days. The best single day was Dec 22, 2022 with a return of +59.7%, while the worst single day was Oct 7, 2021 at -35.4%.

ORIC Pharmaceuticals, Inc. has an annualized alpha of 7.36%, beta of 1.11, and R² of 0.05 versus S&P 500 Index. Calculated based on daily prices since April 27, 2020.

• This stock participated in 204.49% of S&P 500 Index downside but only 125.55% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.05 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ORIC ranks 82 for risk / return — in the top 82% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for ORIC Pharmaceuticals, Inc. (ORIC) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the ORIC Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the ORIC Pharmaceuticals, Inc. was 93.87%, occurring on Nov 7, 2022. The portfolio has not yet recovered.

The current ORIC Pharmaceuticals, Inc. drawdown is 68.17%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of ORIC Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how ORIC Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.